This is the authors' abstract. We don't add key points for this paper.
Domain antibodies such as monobodies provide an attractive immunoglobin fold for evolving high-affinity binders targeting the intracellular proteins implicated in cell signaling. However, it remains challenging to endow cell permeability to these small and versatile protein binders. Here, we report a streamlined strategy combining orthogonal crosslinking mediated by a genetically encoded beta-lactam-lysine (BeLaK) and genetic supercharging to generate cell-penetrating monobodies. When BeLaK was introduced site-specifically to the N-terminal beta-strand of a panel of supercharged monobodies, it enabled efficient interstrand crosslinking with a nearby lysine, generating the rigidified analogs. Compared to the non-crosslinked counterparts, the BeLaK-crosslinked supercharged monobodies exhibited higher thermostability and enhanced cellular uptake at concentrations as low as 40 nM. Most significantly, a +11 charged, orthogonally crosslinked monobody showed significant endosomal escape after endocytosis. The discovery of this stabilized immunoglobin fold should facilitate the design of cell-permeable domain antibodies for targeting intracellular proteins.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Rabb et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: